New solutions are needed for the six million people in the US affected by anaemia of chronic kidney disease.... Jul 17
If approved, Forxiga has the potential to change the treatment paradigm for millions of people in the EU suffering from chronic kidney disease... Jun 28
... Jun 24
This approval follows a priority review designation by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) and marks the first ... Jun 23
First medicine approved in the EU to treat this rare and debilitating genetic condition... Jun 22
In fewer than twelve months, AstraZeneca has worked extremely hard to develop an effective vaccine at no profit and is the second-largest supplier to ... Jun 18
Real-world data demonstrated 92% vaccine effectiveness against hospitalisations due to the Delta variant ... Jun 16
AstraZeneca’s COVID-19 vaccine has been granted emergency use authorization in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for ... Jan 07
Farxiga could become the first SGLT2 inhibitor approved to treat patients with chronic kidney disease, with and without type-2 diabetes... Jan 06
Tezepelumab’s effect on other efficacy parameters was similar to those observed in previous trials, including the registrational Phase III NAVIGATOR trial.... Dec 22
Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80%... Dec 21
This new dosing option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer and once approved, will be available to ... Dec 15
The impact of the disease is significant, with breast cancer responsible for more than 137,000 deaths per year.... Dec 14
COPD is a progressive disease, which can cause obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness and is the third leading ... Dec 14
Enhertu continued to demonstrate impressive efficacy and durable responses in patients with HER2-positive metastatic breast cancer following two or more prior HER2-based regimens.... Dec 10
Interim analysis showed vaccine is effective at preventing COVID-19, with no severe cases and no hospitalizations more than 21 days after first injection... Dec 09
... Dec 08
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained progression-free for a median of 22 months.... Dec 07
AstraZeneca has agreed to sell the rights to Crestor and associated medicines in over 30 countries in Europe, except the UK and Spain.... Dec 01
The NMPA has approved a dosing label update in China for AstraZeneca’s Lokelma to include patients with hyperkalaemia on chronic haemodialysis.... Nov 25
Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in ... Nov 23
CALAVI did not meet the primary endpoint of increasing the proportion of patients who remained alive and free of respiratory failure... Nov 12
AstraZeneca and Amgen today announced positive results from the new medicine tezepelumab in patients with severe, uncontrolled asthma.... Nov 10
Calquence demonstrated superior progression-free survival and favorable tolerability in both previously untreated and relapsed or refractory patients... Nov 09
New indication expands use of Brilinta beyond the cardiovascular disease to patients with mild-to-moderate stroke... Nov 06
-Advertisements-
.jpeg)
Friday, November 22, 2024
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)